The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,318.00
Bid: 12,288.00
Ask: 12,292.00
Change: -52.00 (-0.42%)
Spread: 4.00 (0.033%)
Open: 12,326.00
High: 12,428.00
Low: 12,260.00
Prev. Close: 12,370.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sterling eases off recent highs as investors temper vaccine optimism

Thu, 28th Jan 2021 09:22

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv

LONDON, Jan 28 (Reuters) - The British pound retreated on
Thursday from the multi-month highs it hit in the previous
session, as investors tempered some of their optimism about
COVID-19 vaccinations in the UK.

Sterling surged to its highest since May 2018 against the
dollar in early London trading on Wednesday and later hit an
eight-month high against the euro - a move analysts attributed
to the UK's vaccine rollout being faster than that of Europe.

But the British currency gradually eased off these highs,
falling overnight and opening lower on Thursday.

At 0850 GMT, it was down 0.4% against a stronger dollar, at
$1.3638, compared to its Wednesday high of $1.3759.

Versus the euro, it was down around 0.3% at 88.67 pence per
euro, having peaked at 88.135 in the previous session
.

"We consider Sterling optimism to be excessive and we see
the risk of disappointed expectations. We therefore urge caution
about betting on further Sterling gains," wrote Commerzbank FX
strategist You-Na Park-Heger in a note to clients.

"The markets are clearly ignoring that the current infection
situation in the UK is still very tense," she said.

"There is a high degree of uncertainty as it is difficult to
say how the pandemic is going to develop short-term and when and
how quickly the restrictions can be eased," she added.

Britain has the world's fifth highest death toll from
COVID-19 and Prime Minister Boris Johnson has indicated that the
strict COVID-19 lockdown in England will last until March 8.

The pound has strengthened since a last-minute Brexit deal
was reached in December 2020. But Commerzbank's Park-Heger said
that the impact of Brexit on the UK's economy is still unknown.

The possibility of the Bank of England cutting rates
presents another downside risk for the pound, she said.

Britain said on Thursday that it must receive all of the
COVID-19 vaccines it had ordered and paid for, after some
European Union politicians asked drugmaker AstraZeneca to divert
doses from the UK to make up for a shortfall in supplies.

AstraZeneca was the top drag to the FTSE 100 index
for the second consecutive day.

But some analysts took a positive tone: "The political
jitters between the EU, AstraZeneca and the UK don’t appear to
have a negative impact on GBP. We look for further EUR/GBP
decline over the course of the year as the UK vaccination
advantage (and its likely earlier recovery) and GBP
undervaluation vs EUR are to benefit sterling," wrote ING
analysts in a note to clients.
(Reporting by Elizabeth Howcroft, Editing by William Maclean)

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.